CF Acquisition Corp. VII (NASDAQ: CFFS) announced this afternoon that it is postponing its extension meeting, originally scheduled for June 14, until 10 a.m. ET on June 16.
In connection with the postponed meeting, CFFS has also extended the redemption deadline to 5 p.m. ET on June 14.
The SPAC is currently facing a completion deadline of June 20, but is seeking shareholder approval to extend its timeline by nine months until March 20, 2024. If the extension is approved and implemented, the sponsor will deposit into the trust $0.03 per month for each public share that is not redeemed for each month that is needed to complete a business combination until the deadline.
Although CF VII has not found a target to combine with just yet, it intends to focus its search on the financial services, healthcare, real estate services, technology and software industries. The company is led by Chairman and CEO Howard W. Lutnick, President Anshu Jain, and CFO Jane Novak.
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...